323 related articles for article (PubMed ID: 37237260)
61. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
[TBL] [Abstract][Full Text] [Related]
62. Clinical Predictive Value of Phospholipase A2 Receptor Gene Polymorphism Combined with Subclass of Immunoglobulin G in Renal Tissues for Membranous Nephropathy.
Ji C; Xu Q; Bian X
Altern Ther Health Med; 2023 Oct; 29(7):418-423. PubMed ID: 37535917
[TBL] [Abstract][Full Text] [Related]
63. Combined Serologic and Genetic Risk Score and Prognostication of Phospholipase A2 receptor-Associated Membranous Nephropathy.
Hu X; Xu J; Wang W; Liu L; Jing Y; Gao C; Yu X; Li Y; Lin L; Tong J; Weng Q; Pan X; Zhang W; Ren H; Li G; Kiryluk K; Chen N; Xie J
Clin J Am Soc Nephrol; 2024 May; 19(5):573-582. PubMed ID: 38423528
[TBL] [Abstract][Full Text] [Related]
64. Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature.
Meyer N; Cooper W; Kirwan P; Garsia R; Dunkley S; Gracey DM
BMC Nephrol; 2021 Jul; 22(1):268. PubMed ID: 34294065
[TBL] [Abstract][Full Text] [Related]
65. Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis.
Li W; Zhao Y
Int Urol Nephrol; 2019 Sep; 51(9):1581-1596. PubMed ID: 31140029
[TBL] [Abstract][Full Text] [Related]
66. Effects of hydroxychloroquine on proteinuria in membranous nephropathy.
Cheng YJ; Cheng XY; Zhang YM; Wang F; Wang X; Meng LQ; Liu G; Cui Z; Zhao MH
J Nephrol; 2022 May; 35(4):1145-1157. PubMed ID: 34846713
[TBL] [Abstract][Full Text] [Related]
67. A comparison of clinical features between idiopathic membranous nephropathy patients with and without serum antibody against phospholipase A2 receptor.
Zhang Q; Liu X; Zhang Z; Wu M; Huang B; Zhang Y; Liu B; Qi Z; Shan W; Wang L; Hu Z; Sun Z
Medicine (Baltimore); 2019 Nov; 98(45):e17658. PubMed ID: 31702617
[TBL] [Abstract][Full Text] [Related]
68. [C1q or IgA deposition in glomeruli of children with primary membranous nephropathy].
Xu K; Wang F; Wang ZH; Sun LY; Yao Y; Xiao HJ; Liu XY; Su BG; Zhong XH; Guan N; Zhang HW; Ding J
Zhonghua Er Ke Za Zhi; 2022 Sep; 60(9):901-907. PubMed ID: 36038299
[No Abstract] [Full Text] [Related]
69. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.
Beck LH; Fervenza FC; Beck DM; Bonegio RG; Malik FA; Erickson SB; Cosio FG; Cattran DC; Salant DJ
J Am Soc Nephrol; 2011 Aug; 22(8):1543-50. PubMed ID: 21784898
[TBL] [Abstract][Full Text] [Related]
70. Clinical and pathological features of idiopathic membranous nephropathy in young people.
Lin C; Zheng D; Wang Y; Wang S
Nephrology (Carlton); 2019 Jun; 24(6):599-604. PubMed ID: 30175519
[TBL] [Abstract][Full Text] [Related]
71. Clinical Phenotypes and Predictors of Remission in Primary Membranous Nephropathy.
Jurubiță R; Obrișcă B; Sorohan B; Achim C; Micu GE; Mircescu G; Ismail G
J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34203607
[TBL] [Abstract][Full Text] [Related]
72. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.
Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
PLoS One; 2014; 9(10):e110681. PubMed ID: 25313791
[TBL] [Abstract][Full Text] [Related]
73. Effects of phospholipase A
Yeter HH; Isik Gonul I; Eraslan E; Karacalik C; Ogut B; Guz G
Clin Exp Nephrol; 2021 May; 25(5):488-500. PubMed ID: 33459908
[TBL] [Abstract][Full Text] [Related]
74. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.
Hoxha E; Kneißler U; Stege G; Zahner G; Thiele I; Panzer U; Harendza S; Helmchen UM; Stahl RA
Kidney Int; 2012 Oct; 82(7):797-804. PubMed ID: 22673885
[TBL] [Abstract][Full Text] [Related]
75. [A novel approach to rapid induction of remission in primary membranous nephropathy].
Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
[TBL] [Abstract][Full Text] [Related]
76. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.
Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA
J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027
[TBL] [Abstract][Full Text] [Related]
77. Ultrasensitive Quantitation of Anti-Phospholipase A2 Receptor Antibody as A Diagnostic and Prognostic Indicator of Idiopathic Membranous Nephropathy.
Zhang Q; Huang B; Liu X; Liu B; Zhang Y; Zhang Z; Hua J; Fan Y; Hu L; Meng M; Wu M; Wang L; Hu Z; Sun Z
Sci Rep; 2017 Sep; 7(1):12049. PubMed ID: 28935926
[TBL] [Abstract][Full Text] [Related]
78. The Efficacy of an Initial Prednisone Monotherapy Regimen on PLA2R-associated Idiopathic Membranous Nephropathy.
Bai Y; Liu J; Duan Y; Liu W; Diao Z
J Coll Physicians Surg Pak; 2022 Mar; 32(3):404-406. PubMed ID: 35148603
[TBL] [Abstract][Full Text] [Related]
79. Clinical implications of serum anti-PLA2R levels and glomerular PLA2R deposits in primary membranous nephropathy.
Chaitanya Gunda K; Mathew GG; Balasubramanian S; Sunil Kumar KS
G Ital Nefrol; 2024 Apr; 41(2):. PubMed ID: 38695230
[No Abstract] [Full Text] [Related]
80. Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA.
Kaga H; Komatsuda A; Yamamoto S; Kikuchi T; Kamata M; Sato A; Odaka M; Yokota SI; Takahashi N; Wakui H
Clin Exp Nephrol; 2019 Apr; 23(4):465-473. PubMed ID: 30756249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
